Oxford, UK – 23 June 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray’s GenomeRx Symposium on Monday, June 23, 2014 at The Yale Club, New York.
Oxford BioMedica’s Chief Executive Officer, John Dawson, and Kyriacos Mitrophanous PhD, Head of Research, will take part in a panel discussion entitled “Ophthalmology: Seeing The Future of Gene Therapy Clearly” detailing trends for gene therapy in ophthalmology from 12:45 – 1:40 pm (EDT).
– Ends –